Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal growth factor receptor (EGFR) mutations (NCMs). • BDTX stock is showing notable weakness. See what is driving the movement here.All patients were enrolled at a 200mg oral daily dose of silevertinib. Efficacy and safety were assessed with a Nov. 3, 2025, data cutoff; median follow-up time as of this ...